Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods

IF 3.8 2区医学 Q2 ONCOLOGY

Current Treatment Options in Oncology Pub Date : 2024-04-27 DOI:10.1007/s11864-024-01203-6

Ziyu Kuang, Miao Kong, Ningzhe Yan, Xinyi Ma, Min Wu, Jie Li

{"title":"Precision Cardio-oncology: Update on Omics-Based Diagnostic Methods","authors":"Ziyu Kuang, Miao Kong, Ningzhe Yan, Xinyi Ma, Min Wu, Jie Li","doi":"10.1007/s11864-024-01203-6","DOIUrl":null,"url":null,"abstract":"<p>Cardio-oncology is an emerging interdisciplinary field dedicated to the early detection and treatment of adverse cardiovascular events associated with anticancer treatment, and current clinical management of anticancer-treatment-related cardiovascular toxicity (CTR-CVT) remains limited by a lack of detailed phenotypic data. However, the promise of diagnosing CTR-CVT using deep phenotyping has emerged with the development of precision medicine, particularly the use of omics-based methodologies to discover sensitive biomarkers of the disease. In the future, combining information produced by a variety of omics methodologies could expand the clinical practice of cardio-oncology. In this review, we demonstrate how omics approaches can improve our comprehension of CTR-CVT deep phenotyping, discuss the positive and negative aspects of available omics approaches for CTR-CVT diagnosis, and outline how to integrate multiple sets of omics data into individualized monitoring and treatment. This will offer a reliable technical route for lowering cardiovascular morbidity and mortality in cancer patients and survivors.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"13 1","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-024-01203-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Cardio-oncology is an emerging interdisciplinary field dedicated to the early detection and treatment of adverse cardiovascular events associated with anticancer treatment, and current clinical management of anticancer-treatment-related cardiovascular toxicity (CTR-CVT) remains limited by a lack of detailed phenotypic data. However, the promise of diagnosing CTR-CVT using deep phenotyping has emerged with the development of precision medicine, particularly the use of omics-based methodologies to discover sensitive biomarkers of the disease. In the future, combining information produced by a variety of omics methodologies could expand the clinical practice of cardio-oncology. In this review, we demonstrate how omics approaches can improve our comprehension of CTR-CVT deep phenotyping, discuss the positive and negative aspects of available omics approaches for CTR-CVT diagnosis, and outline how to integrate multiple sets of omics data into individualized monitoring and treatment. This will offer a reliable technical route for lowering cardiovascular morbidity and mortality in cancer patients and survivors.

Abstract Image

查看原文本刊更多论文

精准心脏病肿瘤学：基于 Omics 的诊断方法的最新进展

心脏病肿瘤学是一个新兴的跨学科领域，致力于早期检测和治疗与抗癌治疗相关的不良心血管事件，而目前抗癌治疗相关心血管毒性（CTR-CVT）的临床管理仍然受到缺乏详细表型数据的限制。然而，随着精准医疗的发展，特别是利用基于omics的方法发现敏感的疾病生物标志物，利用深度表型诊断CTR-CVT的前景已经出现。未来，将各种全局组学方法产生的信息结合起来，可以拓展心脏肿瘤学的临床实践。在这篇综述中，我们展示了全息方法如何提高我们对 CTR-CVT 深度表型的理解，讨论了用于 CTR-CVT 诊断的现有全息方法的积极和消极方面，并概述了如何将多组全息数据整合到个体化监测和治疗中。这将为降低癌症患者和幸存者的心血管发病率和死亡率提供一条可靠的技术路线。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.